Particle therapy is rapidly expanding and claiming its position as the treatment modality of choice in teletherapy. However, the rate of expansion continues to be restricted by the size and cost of the associated particle therapy systems and their operation. Additional technical limitations such as dose delivery rate, treatment process efficiency, and achievement of superior dose conformity potentially hinder the complete fulfillment of the promise of particle therapy. These topics are explored in this review considering the current state of particle therapy systems and what improvements are required to overcome the current challenges. Beam production systems (accelerators), beam transport systems including gantries and beam delivery systems are addressed explicitly in these regards.
INTRODUCTION
Light ion beam therapy, or more commonly, particle therapy, is a radiation therapy modality characterized by highly conformal dose distributions and integral dose sparing. There are several possible future horizons for the role of this modality to become the definitive treatment of choice for localized disease. What, arguably, stands in the way of increased accessibility are the financial barrier associated with legacy systems, and achievement of the full physical and biological potential of particle therapy. 1 This review discusses the particle therapy technical and economic challenges and opportunities with respect to particle therapy systems. An assessment of the current state of specific particle therapy systems technology along the lines of the beam production system (BPS), beam transport system (BTS), and beam delivery system (BDS) is provided. Based on the assessment, the critical challenges are identified. Then, potential solutions to the challenges are presented for the individual types of systems. The biologic potential is discussed, but only about the driving technology. The reader is referred to the article "Radiobiological Issues in Prospective Particle Therapy," 2018 (in this issue), for a detailed radiobiological discussion.
Particle therapy systems are effectively now third generation equipment. Before 1990, particle therapy was only performed at research institutions and only with fixed direction beamlines. 1990 ushered in the era of hospitalbased proton systems utilizing rotating beamlines. Between 2005 and 2012, several accelerator types were developed for the specific use of ion therapy, treatment rooms were outfitted with specialized beam delivery systems, patient positioners began using robotics techniques, and new localization imaging methods were implemented. These devices and methods have been summarized elsewhere. 2 Since 2013 most particle therapy beam systems installed in hospitals have performed beam delivery using intensity modulated scanning techniques.
3,4
1.A. Themes and challenges
There are several clinical and accessibility themes related to radiotherapy technology including, for example
• patient care access, • 3-dimensional dose distribution, • target dose conformity, • adaptive radiotherapy, • critical structure dose sparing, • effects of target motion and change, • end of range uncertainty, • patient throughput capability, that are key to identifying the development path of the particle therapy systems. One can explore the requirements of each of these themes and associate them with the properties of the components of the systems to see where breakthroughs may lie in wait.
It is also perhaps useful to consider here some assumptions that have been developed during the decades of particle therapy, which may be associated with the first accelerators and beam delivery systems used. Some example assumptions include:
• proton facilities are more expensive than megavoltage x-ray and electron facilities to purchase and maintain,
• particle therapy facilities are too big to fit in a hospital environment,
• accelerators are expensive and must be improved, • particle therapy requires rotating gantries, • mechanical gantry isocentricity and the Source to Axis Distance (SAD) are important,
• a small Gaussian beam is needed for scanning beam delivery techniques Many of these assumptions can be challenged or at least compared with the cost-benefit ratio when one considers the state-of-the-art particle therapy systems of today and tomorrow.
1.B. Development paths
In identifying the opportunities for future development one can consider particle therapy subsystems such as beam production and beam delivery, among others which will be described herein. Discussion of the types of beam production systems should be done in the context of the beam parameters produced and how they relate to the themes and challenges. What is arguably more important, however, is the interaction between the BPS, BTS, and the BDS and the resulting characteristics of the depth dose and transverse dose distributions that can be achieved and the time it takes to irradiate a single field.
Addressing some of the themes, such as adaptive therapy and organ motion, may require time-dependent beam parameter changes that may require the BPS and the BDS to adapt to the proper penetration depth and transverse distribution required. Which system will be used to adjust a parameter, for example the beam range, will depend upon the timescale of the change required and the system design. At present, patient throughput rate is not limited by the beam flux for the majority of treatment systems since the time to deliver a field is dominated by the imaging and positioning steps. Finally, regarding cost, in big multiroom systems with rotating gantries, the accelerator is not a significant cost driver, but in single room systems and especially if one is considering a single room fixed gantry system, the accelerator will be an important (but not necessarily dominant) part of either the capital or maintenance costs. Comparing the costs of different components relative to the costs throughout the lifetime of the project can help prioritize which subsystems should be studied for cost reduction. The development path of particle beam therapy systems just discussed must take the themes and challenges into consideration to evaluate the relative impact of the various subsystems and the relative gains in treatment quality and efficiency.
CURRENT STATE: BEAM PRODUCTION SYSTEMS

2.A. Beam production system parameters
The BPS critical parameters are energy, energy spread, and timing. The BPS parameters are related to the clinical parameters of the depth of penetration (range), distal fall-off, and field delivery time respectively.
2.A.1. Beam energy
Typically, a beam range of 30 cm of water can accommodate more than 90% of patients coming to a radiotherapy clinic with larger ranges needed to optimize plans requiring beams that enter from the contralateral side and which traverse long bones or metal implants in the pelvic area. For delivery systems that provide lateral spreading only by scanning the beam, a range of 30 cm equates to about 225 MeV for protons and 430 MeV/nucleon for carbon ions. If one is interested in performing ion beam imaging, however, full penetration through the body is necessary. In this case, the higher the energy, the less the beam is scattered as it passes through the body.
2.A.2. Beam energy spread
Although most particle accelerators create nearly monoenergetic beams (full width tenth maximum energy spread % 0.1%), once the beam exits the accelerator it passes through various devices and the patient undergoing range straggling. This process results in a spread of beam energies which contributes to the distal fall-off in the patient. In the case of fixed energy accelerators, one of the devices is a range degrader that is required to set the appropriate depth of the beam and introduces significant energy spread. In some systems, an "energy selection system" can be used to limit this spread. An adequate depth dose distribution can be made across the target even for relatively large energy spreads. 5 
2.A.3. Delivery time
There are several components that contribute to the time it takes to irradiate a field. These can include: Some parameters which are dependent (sometimes partially) on the BPS include the number of ions incident on the patient target volume per unit of time, which may, in turn, be limited by the instrumentation used upstream of the target and the speed with which the ions can be directed throughout the target volume. One example, of the latter, is the time it takes to change the beam energy. The time to mechanically move and verify the range degrader position is dominant for fixed energy accelerators. This time can be from a few seconds to 0.2 seconds. For variable energy accelerators, such as a synchrotron, there can be a fixed or variable cycle time. This cycle time is used to inject the beam, accelerate it to the desired energy, extract it for deposition onto the target, and then a reset to start accelerating another bunch of ions. In most synchrotrons today, this cycle must be repeated each time the beam energy is changed. The total cycle time is characteristic of each specific accelerator and it ranges between 2 and 6 s. That cycle time includes the time to accelerate the beam, which ranges from 0.25 to 2 s, and the delivery time, which can also be either fixed or variable. For a given accelerator, the time it takes to increase the magnetic field in the dipole magnets to a value where carbon ions can be extracted is greater than for protons due to the higher energies needed for comparable ranges in tissue. When patient motion is involved, the cycle time may need to be extended up to 30 s including extended time for starting and stopping the beam extraction one or more times during one acceleration cycle as appropriate to allow beam gating. Note that if 50 energies are required to fill the target from one direction during a treatment session, the dead time (when the beam is being accelerated and not extracted) can be as much as 50 s (1 s per layer 9 50 layers = 50 s). This gives an order of magnitude of the impact of that timing. If the energy changing time were 0.005 s, then the nonirradiation dead time would be limited to 0.25 s for the entire volume. The dead time can exceed the irradiation time for some accelerator types. Given sufficient flux and scanning rate, the full volume might be irradiated in less than 1 s, and perhaps the issue of motion management would become a nonissue.
2.B. Accelerator distribution by type
As of 2018, all accelerators used for particle therapy were either an isochronous cyclotron, a synchrocyclotron, or a slow-cycling synchrotron. All accelerators used for treating particle therapy with an atomic number greater than 1 were slow-cycling synchrotrons. Table I gives the number of each type of accelerator in clinical service.
2.C. Current state: Cyclotrons
As seen in Table I , cyclotrons have remained a mainstay of proton therapy. The major change in these accelerators is the introduction of superconducting magnets in clinical systems. In 2009 the reduced weight (90 tons) Accel (now Varian) isochronous cyclotron treated its first patient. In 2013, the Mevion superconducting synchrocyclotron with even less weight (19 tons) treated its first patient. No cyclotrons are in medical use for ions heavier than protons.
The cost of iron scales by the weight so one can see that the cost (possibly not price) of a cyclotron these days is lower than in previous years. Still, the relative price of a cyclotron in a particle therapy center can be smaller or larger depending on how many rooms are included and whether or not rotating gantries are used.
As of 2018, all cyclotrons used for proton therapy were fixed energy accelerators and therefore used a range degrader to adjust the desired beam energy. 3, 4 Range degraders scatter the beam transversely and generate a spread of beam energies. The scattered beam should be "cleaned" up to create a clinically acceptable beam. An energy selection system is used at a location of large beam divergence to collimate the beam transverse phase space and to limit the beam energy spread. The clean-up collimation reduces the transported beam current, so the beam-current requirements of the cyclotron are increased relative to a variable energy accelerator. Much of the beam is lost in the energy selection system at lower energies. This results in a greater need for thicker shielding at the degrader location with an associated cost. One exception to this is the Mevion cyclotron which is mounted on the gantry and does not use an energy selection system. 6 Through judicious use of materials, the beam lateral and energy spreading is minimized and has been used successfully for clinical operation with a beam scattering system and recently for a scanning system.
2.D. Current state: Synchrotrons
All systems currently installed are slow-cycling synchrotrons. Since 1990, there has not been a significant reduction in the size of synchrotrons for comparable beam energies. However, there have been some improvements in the capabilities of these synchrotrons, primarily to support the speed with which the beam energy can be modified and the control of the beam current extracted. Two improvements implemented in recent synchrotrons (or upgraded older synchrotrons) related to beam energy (penetration), or more specifically, the time it takes to reach the desired energy and one improvement related to beam current (dose rate) control will be discussed in this section.
2.D.1. Acceleration time
The accelerator magnets must have a magnetic field compatible with the injected beam energy. The first clinical hospital synchrotron ensured this by cycling the dipole magnet currents to the maximum value or close to saturation of the dipole steel, compensating for the hysteresis effect which changes the relative correspondence between energized dipole current and magnetic field. This added 0.2 s or about 10% of the accelerator cycle time (see Fig. 1 ). Some carbon ion synchrotrons also use about 10%-20% of their cycle time to overcome this hysteresis effect. Some more recent synchrotrons use an alternative method to provide the correct magnetic field by installing a magnetic field probe in some or all of the magnets and providing a feedback loop to the dipole electric current source. This method can reduce the time for the accelerating cycle by the time it otherwise took to ramp the dipole currents to saturation and back. This reduction in treatment time reduces the chance of patient movement during treatment, reduces the strain on the power supplies improving reliability, and reduces the amount and cost of electricity.
Another energy-related, speed improvement is to quickly change the beam energy extracted from the accelerator, multiple times during each single accelerating cycle. Before 2003, most synchrotrons would extract from the accelerator and send to a treatment room only one ion energy per accelerator cycle. Figure 1 plots the magnetic field in the bending magnets as a function of time during a single accelerating cycle. The red curve shows the bending magnet current when a single energy is extracted from the accelerator. For this proton energy and accelerator, the ions are extracted from the accelerator between 0.6 and 1.2 s and the hysteresis loop is performed between 1.3 s and 1.7 s. For multiple-energy extraction (MEE) per accelerator cycle, the bending magnet current would follow the green curve. In the example shown in Fig. 1 , four energies would be extracted during one cycle.
The number of beam energies required for treatment depends upon the longitudinal extent of the target, the depthdose characteristics of the beam and the treatment plan. For example, for each beam direction, 10-80 energies can be required. At any given depth in the target, a specific number of particles are needed. Note that the number of ions that can be accelerated by a synchrotron is very dependent on the synchrotron design and is somewhat related to the price of the synchrotron. Therefore, a particular synchrotron may or may not have a sufficient number of ions to deliver all that is needed at a given energy during only one extraction cycle. This situation changes for each accelerated energy. Alternatively, there may be an abundance of particles, and these can be distributed over several energies and therefore reduce the number of accelerating cycles which will reduce the time required to deliver the necessary dose. One study for a particular synchrotron has estimated that an average reduction in treatment time across all plans using MEE could be about 50%. 7 MEE has now been implemented at several slowcycling synchrotron-based facilities. 8 
2.D.2. Current control
The third improvement is dynamic extraction control (DEC). With specific intervention, the process of beam extraction from a synchrotron is somewhat stochastic and can be grossly controlled. However, in order to accurately control the dose delivered, depending upon the beam delivery method, extraction control is advantageous. If beam scanning is used, the dose given to every voxel in the scan pattern can be different, and the maximum detectable flux during the scan pattern is a factor in the delivery time. In DEC, the rate of extraction of ions from the synchrotron ring is set for each aiming point of the scan pattern and thus can change at the millisecond time frame. This improvement is primarily needed due to the slow response of existing beam monitoring systems (see the article "Dose Detectors, Sensors and their Applications in Particle Therapy," 2018 (in this issue)).
2.D.2. Compact synchrotron example
An example of a recent compact synchrotron by Hitachi is given in Fig. 2 . 9 The figure compares the footprint of the previous 6-magnet, 250 MeV synchrotron, to the reduced 4-magnet, 220 MeV accelerator. Even more compact designs can be expected to be developed in the future but will require a transition to superconducting technology.
CURRENT STATE: BEAM TRANSPORT SYSTEMS AND GANTRIES
3.A. Beam transport system
A BTS is required between the source and accelerator, and between the accelerator and the beam delivery system. Post acceleration, the BTS transfers the beam between the accelerator and the BDS. The postacceleration part of the BTS must be adapted to the beam parameters such as energy, its spread and transverse dimensions of the beam characterized by its emittance. Positional accuracy of 15%-20% of the spot size at the isocenter is typically required. The needed beam optics are comprised of horizontal and vertical deflection (steering) magnets, bending magnets, and focusing magnets. Beam transport systems are used to direct the beam from the BPS to the BDS, encompass the energy selection system when needed, and transport the beam on rotating gantries.
3.B. Beam transport on rotating gantries and gantry structures
A rotating gantry is a device used to change the direction of the beam relative to the patient. This rotating device consists of magnets, beam diagnostics monitors, collimators, and other instruments mounted on a frame structure. Its role is to deliver the beam to the target (tumor tissue) from the angle prescribed by the treatment plan. The Health Physics Association described several gantry types for photon and electron beam teletherapy in 1974, and in 1996 these were adopted by the IEC. 10, 11 Different gantry layouts are possible and exist, especially for ion beams. The IEC later described gantry types of rotational isocentric, rotational eccentric, stationary, and multiple discrete angles (one radiation head moved between two or more angles) for particle therapy. 12 
3.B.1. Isocentric or eccentric
The labels isocentric and eccentric characterize the relative orientation of the patient with respect to the Gantry. Within each type different geometries are possible. Figure 3 (upper figures) show the general idea of the isocentric and the eccentric gantry.
The most common implementation is the conventional isocentric gantry (see Fig. 3 ), in which the location of the patient is stationary, and the gantry rotates around the patient. The "ideal" point where the beam path crosses the rotation axis of the gantry is generally referred to as the isocenter and is where a to-be-irradiated tumor is positioned.
The eccentric gantry is less common and is characterized by a system in which the patient is not located collinearly with the rotational axis of the gantry. The advantage of the eccentric gantry is the potentially smaller radius and therefore the potentially lower construction costs. In the extreme eccentric gantry (Riesenrad style) there are fewer magnetic elements.
The size and mass of the gantry depend on the particle mass, particle charge, maximum energy of the beam, field strength of the magnets and the required diameter of rotation. High mechanical rigidity is also necessary. The combination of these factors has resulted in massive, threestory high gantries weighing between 90 and 285 tons for proton transport and up to 600 tons for carbon ion transport.
3.B.2. Eccentric gantries
The only rotating eccentric gantry constructed to date was Gantry 1 at the Paul Scherrer Institute. This is shown in the Patient & beam eccentric box in Fig. 2 . In the case of this gantry, the advantage lies in the smaller diameter. 13 The
Comparison of new and old synchrotron designs. By coupling the functions of the quadrupole magnets to the ends of the bending magnets, the new design has reduced the total number of main magnets (bending magnets and quadrupole magnets) to eight. This compares to 16 on the old design. 9 weight is, however, comparable to that of other types of gantries.
In order to achieve this reduced radius, the patient has to be moved vertically and horizontally as the gantry is turned, making the access to the patient more difficult, hence potentially compromising the treatment procedure safety as well as working efficiency for medical personnel.
The full eccentric cabin gantry has yet to be built. Although the idea of rotating the largest bending magnet instead of moving it around is technically simpler, it is not thought to be clinically convenient due to patient access issues and would be quite large; one can imagine the Riesenrad giant Ferris wheel in Vienna to imagine the experience.
3.B.3. Isocentric gantries
There are a variety of geometries possible for isocentric rotating gantries. These can basically be characterized as "Inplane" and "Corkscrew" geometries. The in-plane gantry has all its magnetic beamline and instrumentation in the same plane, while the corkscrew gantry can take advantage of multiple planes in such a way as to reduce the overall length of the system at the expense of extra beam transport elements. 14, 15 A comparison of the space requirements for several different in-plane and corkscrew proton gantries having rotations of 180°and 360°has been provided elsewhere. 16 
3.C. Scanning magnet position
For delivery systems that scan the beam, magnetic dipoles are located in the BTS such that the beam that is incident on the patient target volume is positioned as required. The scanning magnets must be located in such a way that the beam is not misdirected, and the beam optics between the magnets and the target results in the required beam size and position. To date, these magnets, on a gantry, have been located either upstream or downstream of the final bending magnet (see Fig. 4 ). An example of the upstream scanning gantry is Gantry 2 at PSI, 17 while a typical example of a downstream scanning gantry is the Varian Probeam gantry described in Section 3.D.2.
An additional consideration is the effect of SAD on the beam. On the left side of Fig. 4 is the result of an infinite effective SAD, compared to a finite SAD on the right side. An advantageous feature of the upstream scanning is the fact that the beam optics can be designed such that the scanned beams after the bend have effectively parallel trajectories. The upstream scanning layout results in a very large to infinite SAD, thus reducing the skin dose (see Fig. 5 ). Parallel beam scanning systems are considered to be more challenging and more expensive to provide than divergent beam scanning systems. Therefore, the following points need to be considered in relation to the perceived advantage of parallel scanning systems: Farr et al.: Advanced particle therapy systems e958
• To some extent, by forcing optimization functions to minimize entrance dose, modulated scanning optimization can also be used to reduce skin dose.
• Unlike the technical and dosimetric challenges of field matching with scattering systems, 19 robust treatment planning optimization for scanning systems (see "Advanced Treatment Planning" 2018 (in this issue)) provides simple and effective field matching 20 for both parallel and divergent beam geometries.
• The degree of beam divergence from parallelism also depends on the applied field size (smaller approaches parallelism) and SAD (greater approaches parallelism) for divergent beams.
There are several factors contributing to the diameter of a gantry. In addition to the space needed between the mechanical structure and the patient, a gantry with scanning downstream of the last bending magnet would usually have a larger diameter than if scanning was performed upstream of the last bending magnet because sufficient drift space must be allowed between the scanning magnets and the patient. The maximum possible size of the scanned field is determined by the strength of the scanning magnets and the drift space between the scanning magnets and the target. For gantries with scanning downstream, the virtual SAD is usually designed to be at least 2.5 m. A gantry with upstream scanning could usually have a smaller radius. This is because, unlike with divergent beam downstream scanning, there is no field size enlargement at the patient position from upstream parallel beam scanning based on the distance to the patient (observe in Fig. 5 ). However, the aperture of the final bending magnet limits the size of the scanning field, and hence this aperture must be comparably large in order to make scanning through the bend feasible. Significant consequences of passing the scanned beam through this large dipole include beam aberrations and position dependent steering and focusing effects that must be corrected. The large aperture of the last bend makes the upstream gantries heavier, more expensive and more difficult to commission.
It is also possible to implement the combination of both scanning techniques, locating one scanning magnet upstream and one downstream of the final bend.
3.D. Examples of currently operational gantries
3.D.1. Combined accelerator and gantry
Gantry mounted cyclotron concept: H. Blosser first proposed a cyclotron mounted on a rotating gantry for proton therapy (see Fig. 6 ). The cyclotron with a weight of 52 tons and a peak field of 5.5 T producing a 250 MeV proton beam would rotate around the patient. 21 Although the proton version was never built, Blosser's similar concept for fast neutron therapy was built and operated clinically. 22 Mevion S250 proton therapy system: The Mevion system comprises a cyclotron mounted directly onto an isocentric gantry (see Fig. 7 ) without a beam transport system. The weight of the cyclotron is approximately 19 tons. With a peak field of 8.5 Tesla, it accelerates the protons up to the energy of 250 MeV. 23 The protons are extracted into the direction of the patient and are slowed down propagating through the degrader material. The gantry is isocentric and allows 190°of rotation around the patient. Therefore, the full angular coverage of the patient can be achieved by adjusting the horizontal rotation of the patient table. The acceleration and extraction of the beam at all angles of gantry rotation are technical challenges that were initially resolved with the superconducting neutron therapy (48.5 MeV deuterons onto a beryllium target) gantry at Harper Hospital. 21, 22, 24 There are versions of the system in which the beam is laterally scattered and those that employ beam scanning. In the case of the laterally scanned beam, the distribution is shaped via automatically adjustable collimators, whose positions are adjusted independently for each energy. This technology is referred to as Hyperscan.
3.D.2. Proton therapy gantries
Varian probeam gantry: The Varian Probeam system consists of a superconducting cyclotron producing a proton beam at 250 MeV energy, followed by a fixed beamline with the energy selection system (ESS) and an in-plane, isocentric gantry. The gantry makes use of normal conducting magnets with the total weight of above 280 tons (see the layout in Fig. 8 ).
The scanning magnets are located downstream of the final bend, covering a comparably large field of 30 cm 9 40 cm at the isocenter. 25 The gantry can rotate through AE190°(a total of over 360°), hence covering the complete circle. 26 The beamline magnets must be ramped proportionally to the change of the beam momentum. The switching time for two adjacent energies (which usually correspond to approx. 1% of change of the magnetic field) is between 200 and 800 ms depending on the power supply system used.
IBA proteus one gantry: For the Proteus One proton therapy system developed by IBA, the beam is produced by a fixed superconducting synchrocyclotron. The beam is directly fed into the in-plane, isochronous gantry which includes its energy selection system on the inclined part of the gantry ("Magnet 40°" and the following section with the collimation in Fig. 9 ). The fixed beamline and the gantry are based on normal conducting magnets. The gantry rotation angle is 220°, making the horizontal table rotation a necessary issue for covering all possible angles, as it is in case of the Mevion gantry. The scanning magnets are located upstream of the second part of the final bend (see Fig. 9 ). Toshiba gantry at national institute of radiological sciences (NIRS), Japan: Consideration of the size of the gantry and resulting costs are driving the development of several gantry solutions for particle therapy, for example, the HIMAC light superconducting gantry for 430 MeV/u carbon ions (see Fig. 11 ). The gantry is an in-plane, isocentric type consisting of 10 superconducting combined function magnets with a field of up to 3 T. The scanning is performed upstream of the final bend. These magnets consist of two layers of cosine theta windings: the outer layer providing the dipole field component and the inner layer providing the quadrupole field component. The total length of the gantry is 13 m (about half of the length of the HIT gantry), and the weight reaches 300 tons (also a factor of half compared to the HIT gantry).
3.D.4. Shorter gantries
To reduce cost, some concepts have been implemented to reduce the space needed to install a gantry. In the above sections, some gantries were discussed that incorporate a rotational arc of fewer than 360°thus requiring about half the diameter of a conventional gantry. It is also possible to consider methods to reduce the length of a gantry. The first hospital-based gantry at Loma Linda University implemented a Harvard design of a so-called cork-screw gantry layout, where two sets of achromatic bending systems transport the beam. Each of these achromats is in a different plane as to reduce the total length swept by the magnets.
Also, as will be discussed below, a more recent development incorporates superconducting achromats to reduce the distance required to bend the beam, and thereby reduces the length of an in-plane isochronous gantry built by ProNova.
CURRENT STATE: BEAM DELIVERY SYSTEMS
As noted earlier, it is necessary to shape the beam to deliver the desired dose distribution to the target. The BPS accelerates the beam, the BTS tailors the beam and directs it to the BDS. The beam delivery system shapes the beam for treatment. The following parameters can characterize some of the relevant clinical beam properties which are to be delivered for treatment at the target:
It is desirable for the dose distribution to be as conformal as possible (within the context of the dose prescription which can include microscopic disease extension); therefore, the beam must be shaped three-dimensionally. The longitudinal penetration of the beam is given by its accelerator beam energy and any beam modifying devices in the path of the beam. The longitudinal dimensions of the beam will then be given by the range of energies incident upon the patient. The spread of energies (not the end range) in any given energy beam will determine the spread in the dose at the distal edge of the target volume. Any material in the beam path, including the patient, will add to that spread in beam energies and this increases the extent of the distal penumbra. This extent can range from about 1-10 mm depending on the system. 5 The transverse extent of the beam must be controlled to conform to the target. The beam from an accelerator is usually a few millimeters wide, much narrower than most targets. The beam must, therefore, be spread laterally. Until recently, the primary way to spread the beam was to scatter it and obtain a circularly symmetric extended beam which would be shaped by collimators machined to match the projection of the patient target. 27 Recently, however, the field has evolved to see the implementation of various methods to scan a small beam spot across the patient. We refer to this as Intensity Modulated Particle Therapy (IMPT) where the individual field delivery can be uniform or nonuniform, depending on the optimization technique (see "Advanced Treatment Planning" 2018 (in this issue)). A charged particle beam is bent in a magnetic field, in much the same way as the electrons were in an old cathode ray tube television set and the strength of that bend would determine the final position of the beam and thus the shape of the beam cross-section relative to the target. As with all forms of external beam radiotherapy, whether with x rays, electrons, or ions, at the edge of the target the dose distribution is shaped such that the dose decreases from a maximum inside the target to near zero outside the target. The slope of this dose decrease is characterized by the transverse penumbra given by the distance to decrease between two specified dose values. In the case of lateral spreading by scattering, this distance is determined primarily by the distance between the aperture and the patient 28 while, for scanned beams, it is primarily determined by the size of the scanned beam spot, focused at the target. 29 In the latter case, the beam spot is normally in the shape of a Gaussian, and the conformity of the irradiated field will be related to the overall size of that beam.
30,31
4.A. Historical development
The first facility to scan a small spot across the field to generate a fluence modulated dose distribution was in Chiba, Japan in the early 1980s. 32 Not too long after that, the Berkeley group developed a beam scanning system that wobbled the beam to make a uniform fluence distribution followed shortly by the implementation of a raster scanning system. A decade later a discrete spot scanning system was developed at the Paul Scherrer Institut. 13, 33 About the same time, a related scanning system was developed in Russia. 34 Uniform scanning systems that use continuous pattern scanning, but retain physical beam collimation and compensators, also exist. 35, 36, 37 
4.B. Modulated scanning types
The first generation scanning systems operated in a discrete line scan step and shoot delivery method. The system turns on a beam, integrates charge to a planned stopping point, turns off the beam, and then sets the scanning magnets for the next position at which time the process repeats itself until all spots in the row layer have been delivered. The patient positioner was used to move the target into the next line scan position. After an energy layer was completed lineby-line, the next required energy was obtained by range shifting in the nozzle. 32, 33 More recent systems allow discrete lateral scanning (called simply scanning in the remaining text) that scan the beam laterally at a given range in the patient. 17, 32, 38, 39 The BPS controls the beam range in these systems. Discrete scanning is currently the most commonly used type but suffers from scan speed limitation due to the requirement of turning on/off the proton beam for each spot, and for the time the beam monitors need to collect and process signals. The number of spots can be thousands per field delivery. Continuous scanning is a method which does not turn off the beam between planned irradiation spot positions. 40, 41 According to the IEC, modulated scanning (IMPT) is a "scanning mode wherein a small diameter light ion beam is scanned across a target to create a field large enough to cover the target such that the intended fluence delivered to the patient can be different at different lateral locations." 4 This can be done in a dose driven manner by modulating charge required at each voxel, independent of the beam fluence rate, or in a time driven method controlled either by the speed of the beam scan at a fixed beam fluence rate, or a variable fluence rate at a fixed scan speed, or a combination of both. A control system is required for scanning and operates via control points along the scan path.
PARTICLE THERAPY SYSTEM CHALLENGES
In the previous sections, the discussion has concentrated on the background and status of existing systems. These systems have been discussed regarding their capabilities, strengths, and weaknesses concerning the themes and challenging opportunities. In this section, the development path of these systems is addressed, again in the context of the opportunities to address the important themes and challenges of the field.
5.A. Economic challenges and opportunities
The major challenges to widespread use of ion beam teletherapy are economic. The cost to implement and use it is currently significantly higher than photon teletherapy. Some technical changes could be resolved, however, to reduce the economic considerations. Vatnitsky and Moyers (2013) provided some cost scenarios for a four room proton only and a four room proton plus carbon facility over a 25-year operating lifetime. 2 The cost of a synchrotron accelerator compared to the total cost incurred was less than 1% for the proton only facility and 2% for the proton plus carbon facility. The highest cost of running a facility was salaries, the second highest was supplies, and the third highest was maintenance costs. These three items will be discussed in reverse order.
5.A.1. Maintenance costs
There are a variety of contributions to the maintenance tasks required for a particle therapy facility. These can include:
• Preventive maintenance, • Corrective maintenance and • Upgrade work.
Most facilities depend upon a maintenance contract (provided by the vendor) which is currently set by market acceptance rather than actual costs and is typically about 10% per year of the initial purchase price. This includes replacement parts, supplies, and maintenance personnel.
The activities associated with this maintenance take time; time which could otherwise be used in the delivery of patient treatment, quality assurance, or research and development activities. There are two sides to this reality. On the one hand, most maintenance contracts have a penalty clause wherein if the system is unable to be used for patient treatment more than a certain fraction of the scheduled time; the vendor will pay some percentage of the lost revenue. On the other hand, in order to ensure high uptime, the level of maintenance tasks may be increased requiring more maintenance time than might otherwise be necessary, and thus reducing the systems available treatment time. The availability of the system for patient treatments greatly affects the incoming revenue and thus has a large influence on the financial success of the facility.
Example data of availability for a facility having equipment with low downtime and a maintenance contract favorable to patient treatments are given in Fig. 12 . The pie graph shows the availability of different beam uses at Loma Linda University (LLU) where 100% equals 24 h per day, 7 days per week, 52 weeks per year. At this facility, the beam was typically unavailable for use by the hospital only about 16 h per week due to scheduled or unscheduled maintenance. During periods of significant upgrades, less beam time was available. The success of a facility will, therefore, depend upon either a favorable service contract or reliable equipment or both.
Another example of availability is the Massachusetts General Hospital proton therapy system that has an internal maintenance staff with normal maintenance times that account for fewer than 8 h per week allowing ample time for patient treatment, physics, and technical developments.
With a typical uptime of over 97%, as calculated by contract definitions, most systems are getting close to the statistics of a conventional photon radiotherapy system, but they are not at that level yet. The challenge, therefore, is to find opportunities to reduce maintenance without compromising treatment availability and to deal with obsolescence and capability upgrades in an efficient and low-cost manner. This requires up-front design considerations in these facilities.
5.A.2. Supplies and operational costs
Operational costs include many items, including consumable products and salaries. The cost of some supplies per patient, such as dressing gowns, rectal balloons, and blankets, can be reduced by reducing the number of treatment fractions. The cost to the patient is an important factor in the acceptance of particle therapy. Costs can be further reduced by reducing the number of patient-specific hardware items such as apertures and boluses. This is one of the advantages of beam scanning which, for most treatment sites is delivered without this hardware. On the other hand, this may have the undesirable effect of reducing conformality for some treatment sites.
The relative cost of salaries compared to revenue can be offset by treating more patients per shift or month and bringing in more revenue. This includes reduced fractionation schemes and shorter treatment times. Extending hours to accommodate more treatments will require additional staff, but perhaps not proportionally. Higher automation could reduce the salary cost as well. Improved treatment planning software, systems automatically compensating patient setup misalignments, and efficient quality assurance methods could reduce the working time of personnel.
5.A.3. Particle therapy treatments cost to financial performance ratio
Since about 2003, the number of proton facilities has increased rapidly. The number of facilities with capabilities of delivering particle therapy with an atomic number greater than 1 has increased much slower due to either concern about relative efficacy when compared to protons and the higher cost, or both. As of 2015, about 136,000 patients had been treated with protons, and 16,000 patients had been treated with carbon ions. Although the facility at Hyogo, Japan is capable of treating with helium ions as well as protons and carbon ions, they have treated only a few patients with helium ions. The only facility to treat a large number of patients with ions other than hydrogen and carbon was the Lawrence Berkeley National Laboratory (LBNL) which also used helium, neon, silicon, and argon ions. 16 Recently there has been renewed interest in the use of helium-4 ions because they provide a theoretical lateral penumbra width about half that of proton beams but do not have as large a fragmentation tail, or the radiobiological issues associated with carbon ion beams. LBNL treated over 2000 patients with helium ions between 1957 and 1993 with insurance companies providing coverage for its use for eye and arteriovenous malformations. 42 Several facilities are currently preparing helium ion beams for patient treatments, and several proposed facilities include this capability.
The expansion of light ion therapy with Z > 1 is economically attractive because of the opportunity to realize additional hypofractionation. Hypofractionation can have an important economic impact. It allows an increased throughput of patients per year, thereby reducing the cost per treatment. It is also desired by the patients to have shorter courses of treatment. Hypofractionation is a growing trend in photon therapy whereas progress in proton therapy hypofractionation has been comparably slow. However, progress is being made in proton therapy hypofractionation with clinical trials and registries becoming more widespread and organized.
For stereotactic radiosurgery (SRS), the degree of conformity required at the target lateral edges is extreme. Any simple biologically effective dose calculation quickly illustrates that excess dose to adjoining critical structures cannot be tolerated with large fraction sizes. Geometric sparing is the fundament of hypofractionation enablement. To date, proton SRS has only been performed with high accuracy patient positioning systems and older, nonscanned proton therapy, using physical beam trimming devices. 43 This is because the spot size of current scanned proton therapy systems is too large for this application. The situation is similar for stereotactic body radiation therapy (SBRT). In photon practice, SBRT has resulted in improved patient outcomes for some lung, pancreatic, and liver cancers. Although initial studies have been performed for proton SBRT, 44 the application has been slow to gain acceptance. Most likely this is due to the additional uncertainties of proton SBRT, namely uniform dose deposition to a mobile target.
If the challenges of particle therapy hypofractionation can be overcome, larger fractional doses, SRS, and SBRT techniques could play a major role in improving the cost to financial performance ratio. Together, with reduced capital and operating costs, the goal should be to bring the cost-to-performance ratio to that of photon treatments.
5.B. Beam delivery system challenges
There are a variety of desired aspects of system performance which particle therapy has the promise to achieve, but whose promise has not yet been fulfilled. In the ideal system, one would like a high degree of medically necessary conformality with an appropriate level of robustness when applied to all treatment sites, including those involving organ motion. It should also be possible to rapidly adapt the delivery due to a change in patient condition.
5.B.1. Static target conformity
Although proton therapy offers integral dose sparing in comparison to photon therapy, it is not necessarily more conformal in the high dose region. This can be attributed to fewer beam entry angles, multiple Coulomb scattering of protons at depth in comparison to photons, and the relatively wide penumbra of proton scanning systems in comparison to those using physical beam limiting devices (collimators). The results of a study reporting on this are shown in Figs. 13 and 14. In the retrospective study, a cohort of 7 head and neck patients from helical photon therapy clinical practice were selected for IMPT replanning. 45 The target volume doses were evaluated using a conformity index metric and compared to each other. Fig. 14 illustrates the resulting situation where the helical photon plans had greater conformity to the target for the majority of the plans when doses greater than 40% where considered, whereas IMPT provided higher conformity (essentially volumetric sparing) below this level. These results have further implications for the ideal application of proton therapy.
5.B.2. Organ motion and robustness
It is generally accepted that the effect of patient tissue motion has a bigger impact in particle therapy than in megavoltage x-ray teletherapy due to the finite range of the ions. The use of moving beams (e.g., scanning a pencil-like spot beam) simultaneously with moving tissues complicates the matter even further. An example of the resulting inhomogeneity from slow delivery scanning systems is shown in Fig. 15(ii) . This represents the case where mitigation measures are not applied.
Ideally, advanced delivery techniques should be developed (Section 7.B) to obviate the need for clinical mitigations. Until then, some clinical techniques to mitigate the effects of motion are in use for particle therapy (see "Motion management in particle therapy," 2018 (in this issue)).
5.C. Comparison of beam delivery systems
Arguably, some of the most significant technological advances in particle therapy are observed in the BDS. Although many ion centers still use scattering, the transition to IMPT in new centers, as well as the updating and expansion of existing centers is universal. Unlike scattering BDSs, IMPT is programmable. Scattering irradiations are uniform field for field whereas modulated scanning irradiations can be uniform or nonuniform (see "Advanced Treatment Planning," 2018 (in this issue)). The preparation and workflow between scattering (including uniform scanning) and IMPT is also substantially different. Scattering and uniform scanning deliveries require extensive patient specific collimation fabrication and collimator interchanges in between fields (unless multileaf collimators are used) and quality assurance (QA). Whereas field conformity is relatively similar between scattering systems, depending primarily on distance from collimation, 28 the spot size is an additional, and usually dominant determinant of conformity for IMPT systems. 29, 31 The beam spot profile is typically approximated by treatment planning systems as a Gaussian distribution or the sum of more than one Gaussian distribution.
Individually, the advantages and disadvantages of modulated scanning (IMPT) in comparison to scattering deliveries are listed in Table II .
These comparisons are helpful in focusing the development path. By identifying the limitations of a modality compared to another, one can learn the parameters that constrain FIG. 15 . Demonstration of target motion -scanned proton beam delivery interplay effect: (i) dose delivery to static target (ii) dose perturbation resulting from high Z object (simulating bone) proximal to target with single energy layer scans (iii) same as (ii), except 6 volumetric energy scans. Fundamentally, the uncertainty is related to the accurate dose calculation and placement of the Bragg peaks within the target. 46 Table III presents the characteristics to be improved for the next generation of particle therapy systems to meet the challenges of improved cost to performance ratio, and improved patient outcomes, realizing the full promise of particle therapy. Note that relative terms are, in the authors' opinions, relative to performance in currently operating systems.
5.D. Technical requirements for next generation of particle therapy systems
NEW HORIZONS: BEAM PRODUCTION SYSTEMS
There are a variety of desired aspects of system performance which particle therapy has the promise to achieve, but whose promise has not yet been fulfilled. In the ideal system, one would like smaller, lower cost systems with a wide energy range, quick energy selection, and highly controllable currents. One must keep the desired parameters in mind when considering innovations. It is not sufficient to adopt a new beam production system because it seems different, it is important to understand the workflow and how such a system is integrated into a particle therapy facility for optimal patient treatment. Unfortunately, progress on the DWA and FFAG accelerators has not been as fast as hoped and these accelerators have not yet come to fruition.
6.A. Nonrealized accelerators for the clinic
6.B. New horizons: Cyclotrons
There appears to be a trend to move to more superconducting cyclotrons. The smallest are superconducting synchrocyclotrons, but these deliver pulsed beams which are not optimized for some forms of beam scanning. On the other hand, although the weight of existing superconducting isochronous cyclotrons is less than that of room temperature cyclotrons, the overall size (Mevion as the exception) is not different. Comparatively, normal conducting cyclotrons have a field strength of upwards of 3.0 T whereas the superconducting field strength of the Mevion system is stated as 8.5 T. Development is now concentrating on these high field strength superconducting isochronous cyclotrons with continuous, controllable beam current. Perhaps these shall become the standard with normal conducting cyclotrons reaching end-of-life. In the earlier days, these accelerators were implemented with double scattering systems, and energy changes were accomplished with ridge filters or range modulator wheels in the BDS. However, with the growth of scanning technology, as has been noted earlier in this paper, the time required to change the energy during beam delivery is an important factor. Owing to improvements in beam transport magnetic field changing times, and fast cyclotron degraders, beam energy change times in some cyclotron systems have been reduced to sub 100 ms timeframes. There may still be room for improvement. Fig. 16 .
It also promised to eliminate the Achilles' heel of cyclotrons -the need for external energy degradation. Energy degraders reduce beam flux by up to 99% at lowest energy, generate component activation, and require massive shielding. The new design promises to provide continuous beam energy variations without the use of an energy degrader. It will do so by using variable magnetic field intensity. It is hoped that the concept could be extended to the acceleration of other ions. Energy change times may be limited by magnetic field ramping rates, however, which may provide approximately 20 MeV/s.
6.B.2. Cyclotrons for ions heavier than protons
The idea of building a cyclotron for accelerating heavier ions has been evolving, but singular units are massive device designs of at least 400-550 tons. 47 Using "traditional" iron yoke superconducting techniques, IBA has also proposed a 700-ton superconducting isochronous cyclotron for particle therapy (Fig. 17) , accelerating particle therapy ions of charge to mass ratio ½ including carbon, and up to argon for research purposes. The accelerator has a proposed radius of 6.6 m. 48 One of the challenging aspects of such an accelerator is to incorporate the ability to produce different ions. One technique used is to take advantage of the cyclotron acceleration equation and to accelerate q/A = 0.5 ions. 47, 48 This, of course, will require a particular ion source (or sources) to create the ions with the appropriate charge. In such a way it is possible to use a fixed magnetic field, independent of the ion species (within the q/A constraint), although if it is determined to be clinically appropriate, some simplification results from choosing only carbon ions. Considerable effort in the design was devoted to obtaining sufficient turn separation at the location of extraction. 49 Recently, a set of coupled cyclotrons has also been proposed with the larger accelerating stage weighing about 100 tons. 50 
6.C. New horizons: Synchrotrons
Synchrotron performance strives for increased current output and control, as well as faster energy changing time. Nowadays the extracted duty factor (smoothness of the extracted beam) has improved from 100% variation in some machines to extraction stability of better than several percents in some cases. This can potentially enable the use of continuous beam scanning with synchrotrons.
6.C.1. Rapid cycling synchrotrons
One method to increase the time-averaged flux from a synchrotron is to have shorter cycle times with fewer ions injected per cycle thereby increasing the current output while keeping the accelerated charge below the space charge limitation. Several rapid cycling synchrotrons (RCSs) have been proposed during the last 15 yr. The most mature RCS being developed for clinical use was previously summarized elsewhere, 2 but this system is still in the development stage. In addition to the potential to have a higher average beam flux, a rapid cycling operation mode can provide rapid energy changes since the beam can be extracted at a different energy during each cycle. Note that since an RCS is a pulsed system, it would seem suitable for use with spot scanning. A current disadvantage of RCSs for use with the modulated scanning technique of delivery is, however, that the current stated cycle rate is 15 cycles per second which is much slower than the lateral scan rate of current systems that may provide an average of more than 400 spot aiming positions per second. As treatment volumes often require more than 10,000 spots, many accelerator pulses will be required. It is, however, unlikely that one can depend upon the charge in the pulse within a few percents of accuracy, so a few to several pulses may be necessary at each spot aiming location, increasing the irradiation time. Further considerations include potentially the need for specialized dosimetry instrumentation (see "Dose detectors, sensors and their applications" 2018 (in this issue)) to deal with the very short, but high peak charge pulses, as well as the potential biological effect that would have to be studied.
6.C.2. Superconducting synchrotrons
The use of superconducting magnets is expected to provide further size reduction for synchrotrons. Currently, a superconducting heavy-ion synchrotron is being designed at the NIRS, Japan. The design uses a new ARC-ECRIS source 51 capable of producing multiple ion species. The source is expected to produce carbon 5 + ions. Plans include the development of a laser-driven injector where a focused high-intensity laser will be directed to a carbon foil; carbon ions are to be produced and accelerated up to around 4 MeV/ u. This will inject into the superconducting synchrotron. The superconducting synchrotron consists of four curved combined-function (dipole and quadrupole) superconducting magnets at 90°. The resulting design (Fig. 18) , about half the size of the existing carbon ion synchrotrons, has a circumference of 28 m and is 7 m long on each side. The intent is to combine the compact synchrotron with the proposed compact carbon ion gantry (see Section 6.H.3), both using superconducting technology. Together, and using the laser injector, a single room carbon-ion treatment system might be completed in a footprint of 14 m 9 25 m. [51] [52] [53] 
6.D. New horizons: Linear accelerators
Linear accelerators (LINACs) accelerate beams in a straight path obviating the need for bending magnets. LINAC acceleration is provided by a single pass of the charged particle through a series of radiofrequency (rf) cavities. Drawing power from megawatt high power rf sources, typically klystrons, an axial, linear accelerating gradient is produced. Gradients of 20 MV/m represent conservative designs, but new higher gradient structures are being developed. 54 The LINAC accelerating structures can be arranged serially in a modular manner whereby the total accelerating potential is merely the gradient times total length. Given the modular nature, higher energy, or indeed heavier ions of the same Z/A may be accelerated by adding additional cavities and power supplies. Commercially available combinations of S-band rf modulators and klystrons are available providing repetition rates of about 200 Hz.
Electron beam LINACs are the most commonly used accelerators in teletherapy, but LINACs have yet to be adopted in particle therapy. LINACs have some desirable characteristics: modularity, high flux, small emittance, high efficiency, and electronic energy control. Modularity offers advantages for installation, commissioning, moving location/ transportation, maintenance, and dismantling. Small emittance enables smaller spot sizes. High flux can provide shorter treatment times together with rapid electronic energy changes at the LINAC repetition rate (200 Hz). The ability to control the energy in the LINAC, without the need for moveable absorbers may result in reduced ion losses, less induced radiation, lower shielding requirements, and reduced costs. The small emittance allows the use of narrow diameter, lightweight beam transport lines, and gantries, also reducing cost.
The idea of using a LINAC for particle therapy has been considered for some time, and conceptually developed by the TERA foundation at CERN. [55] [56] [57] The CERN spin-off company Applications of Detectors and Accelerators to Medicine (ADAM SA) is now building a full LINAC proton therapy system called LINAC for Image-Guided Hadron Therapy (LIGHT). The major components of the LIGHT accelerator are shown in Fig. 19 . The ion source injects protons into a 750 MHz radiofrequency quadrupole (RFQ) developed by CERN. 58 The RFQ accelerates the protons to 5 MeV and passes them through a series of side-coupled drift tube LINACs (SCDTLs). Due to their relatively high impedance, the SCDTL structures are ideal for accelerating the protons to 40-70 MeV. 59 Following the SCDTLs are a series of Coupled Cavity LINACs (CCLs) that accelerate the protons to the needed energy, 230 MeV for the LIGHT system. The total length of the LIGHT system is 24 m from source to exit. The required length is principally based on the accelerating potential of the cavities. This design is based on an accelerating potential of 18-20 MV/m. A proportional reduction in system length could be obtained by using higher gradient cavities with over 50 MV/m of accelerating potential. 54 LINACs are high flux devices by nature. Therefore higher dose rates may be possible, but the design goal of the first LIGHT machine is 2 Gy/min.
6.E. New horizons: Beam instrumentation
One severe limitation to decreasing the treatment time involves the beam instrumentation used. Currently, most beam monitoring systems use large-area gas-filled ionization chambers to measure the spot flux and segmented gas-filled ionization chambers to measure the spot position, shape, and size. Due to ion diffusion times, electron flow through cables, computer processing time, and network transmission times, compared to possible ion delivery times these monitoring systems require a relatively long time to process the signal and provide feedback to the accelerator extraction system. The accurate control of dose delivery is of paramount importance for all delivery systems. Because of beam instrumentation limitations together with the large fluctuations in flux extracted from some older legacy synchrotrons, to accurately control the delivered dose, one had to err on the side of lower flux in expectation of the sometimes higher flux to ensure that the detectors and feedback systems would be able to respond quickly enough.
For modulated scanning systems implemented before 2011, most synchrotron-based systems decreased the extracted flux for each energy to allow several measurements at each spot aiming location to provide an accurate measurement and feedback to the extraction system. This is because, at high flux, aiming locations needing a small number of ions would only have a single measurement. A more straightforward but less precise way of saying this is that the flux was lowered so that the smallest dose spot could be accurately measured. Unfortunately, this method decreased the flux at all aiming locations for a given energy even though some locations needed a high fluence. This leads to an increase in the total time required to deliver the treatment, allows more motion of the patient during delivery, and reduces the number of patients that can be treated per day. Setting a lower threshold for the minimum deliverable proton quantum per spot would also require faster detector and analysis systems (see "Dose detectors, sensors and their applications" 2018 (in this issue)). Another limiting method is to constrain the minimum number of particles required for each spot with the treatment planning system. However, this can degrade the treatment plan quality (see "Advanced Treatment Planning," 2018 (in this issue)). The Siemens Iontris has implemented a dynamic extraction control method whereby the treatment plan spot map is analyzed and the desired flux is optimized for each spot (within a reasonable range). The synchrotron settings can then be controlled according to the plan. In this method, the synchrotron filling may be maximized and treatment times are shortened.
6.F. New horizons: Time available for treatment
One of the most important methods of reducing the economic challenge is to reduce the cost and time of acquisition, commissioning, QA, and maintenance of the facility. The reliability of the facilities has to be secured to a higher degree than in accelerator facilities used for research, in order to avoid unscheduled interruptions of the treatment and to reduce the time of the technical shutdowns. These include daily machine related work that limits the time in which the patients can be treated, as well as more seldom (but still regular) shutdowns for several days for the larger technical maintenance. Some methods available to medical physicists include using Monte Carlo simulations to help with commissioning, streamlining routine QA tests, and performing less patient-specific QA measurements. The largest impact will be provided, however, by developing robust equipment that requires little time for maintenance.
6.G. New horizons: Fast beam angle switching
Between 2000 and 2013 several different rotating gantry types were developed and installed in clinical facilities. A graphical comparison of their sizes and room layouts were previously published in 2013. 2 None of the installed systems is, however, currently capable of arc therapy or light ion volumetric modulated arc therapy (LIVMAT). Some groups currently believe that this will improve patient treatments, while other groups believe that the modulated scanning modality enables highly conformal treatments, with critical structure dose sparing without the need for many beam delivery angles. Computer controlled beam steering and focusing have improved beam tuning over the years, but no gantry has yet demonstrated rapid beam delivery at multiple gantry angles. Retuning of the switchyard may slow treatment times thereby reducing revenue and allowing more motion of the patient. Beam tuning times for LIVMAT or multiple-discrete angle treatments may be reduced if the accelerator is directly mounted on the rotating gantry. The Mevion system has two concentric gantries, one for holding the cyclotron and one for holding the beam monitoring and shaping equipment. 2 Whether this dual gantry system can react fast enough to deliver many-angle treatments is currently unknown. Moyers proposed mounting a dielectric wall accelerator (DWA) around the periphery of a Ferris wheel type rotating gantry for both LIVMAT and ion beam computed tomography.
2 Currently, however, the development of DWAs is slow. Danfysik has similarly proposed mounting a synchrotron around the periphery of a rotating gantry, 60 but this system is likewise not under production (see description in Section 6.I.1).
6.H. New horizons: Superconducting gantries
6.H.1. The effect of superconducting magnets on proton and heavier ion gantries
The so-called beam rigidity, the measure of how much magnetic bending power is required to focus or bend the beam, is higher for beams of ions with Z > 1 than for protons. For example, the beam rigidity for a carbon ion beam is Bq ≤ 6.8 Tm compared with Bq ≤ 2.4 Tm for a proton beam. This results in the necessity to use many long magnets in an ion gantry if the magnetic field is kept to a level achievable by a room temperature magnet. 61 Consequently, the use of superconducting magnets can have a very noticeable effect on the size of an ion therapy gantry, since they have much higher magnetic fields than their normal conducting counterparts. The fact that the beam bending radius dictates most distances in a gantry operating with heavier ions means that increasing the magnetic field by a factor of two could reduce the path of the beam in the gantry by almost the same factor.
The beam rigidity of a proton therapy beam is, however, lower. Therefore, the number and the length of the magnets in a proton therapy gantry is smaller. The gantry size is instead dictated by the beam optics considerations as well as space requirements for patient equipment and beam delivery systems (e.g., scanning system). 17 Providing a stronger magnetic field reduces the length of the dipoles, but the effect on the gantry size will very much depend on the particular design.
6.H.2. Challenges in using superconducting magnets
There are a number of challenges associated with the use of superconducting magnets on a gantry. The mechanical design of the magnet structure requires high mechanical stability to counteract the effects of the Lorentz force induced by the strong magnetic field. Also, strong magnetic fields extend outside of the magnets because no (or little) iron is used to confine them. This can be a problem at the location of the isocenter, for which most medical facilities require a strict magnetic field limit of < 0.5 mT. This is done so that the field does not interfere with the anesthetic equipment, artificial pacemakers, Cochlear implants, etc. 62 The field can also interact with the iron in the surroundings, e.g., in heavy iron reinforced concrete walls, hence distorting the required magnetic field properties in the good field region of the magnet and thereby impacting beam delivery. This means that, eventually, shielding of the magnetic field is required. This can be either passive, made of the ferromagnetic material such as iron, or active, if some smaller additional coils are used to compensate for the field extending outside of the main magnet.
Another challenge is presented by the fact, that the beam losses in the gantry, which are present in most current normal conducting facilities, could create hot spots in a superconducting magnet. This can cause quenching of the magneta sudden loss of the superconductivity -that can lead to the immediate shutdown of the magnet and the gantry or even damage of the magnet. In order to prevent this from happening, the current in the magnet must be limited, so it does not reach the critical current for the given temperature, hence effectively limiting the magnetic field strength. One also needs to develop a sufficient cooling concept, which includes a quench protection system, limits the consequences of the quench and allows fast recovery from it. This implies providing minimal warm up and cool down times of the cold mass.
The energy of the beam is modified during the treatment process in order to cover the whole volume of the tumor. In the ion therapy facilities operating with normal conducting magnets, the magnets in the beam transport system are ramped proportionally to the momentum of the beam. The required ramping speed (including the reaction time of the sensors and electronics) is usually in the order of 1%-10% of the maximal B-field per second. This is a rate, which is quite difficult to achieve for the superconducting magnets since the magnetic hysteresis and the eddy-currents could warm up the magnet, hence causing a quench. There are two possible solutions. The first one, as adopted in the Toshiba gantry at NIRS described in subsection 5.D.2, is implementing a large number of cryo-coolers (34 in total, in case of the Toshiba gantry) in order to provide sufficient cooling despite the fast ramping. This solution is, however, comparably costly. The second option is to develop a beam gantry optics with a very large momentum acceptance, such as the gantries based on FixedField Alternating Gradient (FFAG) approach, described in subsections 8.B.3.
The fast change of the beam momentum could allow the volumetric scanning of the tumor tissue on the time scale of several seconds. Such a fast beam application could make the treatment of the moving targets more feasible and practicable, either by implementing the gating procedure or by averaging out the errors by rescanning the tumor tissue several times. 63 
6.H.3. Examples of superconducting gantry designs
ProNova SC360 gantry: The ProNova company has proposed one design of a proton therapy gantry based on superconducting magnets. 64 The gantry consists of two superconducting bends, each comprising two dipole magnets with three quadrupole magnets between them (see Fig. 20 ). All five magnets of each bend are embedded into one cold mass.
Each bend is separately achromatic, which allows for a relatively large momentum acceptance in the gantry of around AE3%. Between the bends, there are a number of normal conducting magnets. The beam generation, energy switching, and selection are performed upstream of the gantry. The beam is scanned downstream of the final bend.
While the overall magnet weight is a bit lower than some gantry systems (but not all normal temperature gantry systems), the overall weight also includes requirements of gantry structure rigidity and results in a total less than 100 tons. An important feature of this gantry is its small size. It is about ½ the length of other gantry systems and almost as short as the corkscrew gantry design.
Superconducting gantry proposal for Christie hospital:
Design of a 330 MeV superconducting gantry is currently in development at the University of Manchester. 65 It is an isocentric design aimed at transporting the proton beam of the energy up to 330 MeV to the patient location. Such high energy is not necessary for treatments using the Bragg peak technique; however, it can be useful for computerized tomography performed with the proton beam, which could lead to reduced range uncertainties, since the tumor diagnostics and treatment would be performed with the same particle type. conducting quadrupoles. The gantry has a comparably small radius of 3.5 m (see Fig. 21 ).
Superconducting gantry proposal for the National Institute of Radiological Sciences (NIRS), Japan: Building on their experience of the superconducting carbon gantry now in service (see Section 3.D.3), the group is further developing the technology using higher field strength magnets. The goal of the project is to produce a carbon ion gantry that is about the same size as a legacy normal conducting proton gantry. The new design uses three combined function superconducting magnets providing both dipole and quadrupole fields with the maximum fields of B = 5 T and maximal gradients of G = 15 T/m. Figure 22 compares the layouts of the new design and of the existing NIRS superconducting carbon ion gantry. The new design achieves an overall length of 5 m in comparison to 13 m from the existing gantry, and the beam orbit radius is 4 meters in comparison to 5½ meters respectively. 52 Nonscaling fixed field alternating gradient gantry proposal: The Fixed Field Alternating Gradient technology is a concept for constructing an accelerator or beamline using cells composed of several, typically three, quadrupoles with an alternating gradient. 67 This arrangement allows transporting beams of different energies through the beamline without changing the magnetic field of the quadrupoles. The concept was first implemented in the Electron Machine for Many Applications (EMMA) at Daresbury Laboratory in the UK. A design of superconducting gantry based on FFAG technology has been proposed. 68 In the proposal, the gantry consists of 22 cells, each composed of three superconducting quadrupole magnets (see Fig. 23 ).
The gantry has a comparably large radius of 7.5 m and would allow a very high momentum acceptance of up to AE15%. Such momentum acceptance covers a large share of the momentum range required for ion therapy (which is usually around 50% of the maximum momentum). It would allow a fast volumetric scanning described in subsection 8.B.1 without the ramping of the magnets, providing additional treatment options. PSI superconducting gantry with high momentum acceptance: Another design of high-momentum acceptance gantry has been proposed at the Paul Scherrer Institute. 17 The design comprises a bend consisting of three superconducting combined function magnets, accompanied by two normal conducting magnets, with a total momentum acceptance of AE12.5%. In this design, the degrader is installed directly on the gantry, and no energy selection system is implemented (see Fig. 24 ).
For this gantry, a set of Canted Cosine Theta (CCT) combined function magnets have been developed at the Lawrence Berkeley National Laboratory. 69 Another magnet design alternative based on the racetrack geometry has been designed at Paul Scherrer Institute. 70 The magnets are to be cooled with the cryo-coolers directly mounted on the cold mass. The scanning is proposed to be implemented downstream of the final bend.
6.I. Combined accelerator and gantry concepts
6.I.1. Synchrotron and gantry
During the late 1980s, it was apparent that the diameter of a 250 MeV proton synchrotron and the diameter of a rotating gantry for the same energy were similar and multiple ideas to rotate the synchrotron on the gantry were proposed. Various groups developed a single room concept to place an injector, a synchrotron, and a beam transport system onto a rotating gantry. Later Danfysik expanded the concept to provide proton energy up to 283 MeV for proton CT and 3 He 2+ ion energies up to a maximum of 136 MeV/u, corresponding to ranges in water of 460 and 100 mm respectively. The entire system could be rotated, so the angle of the beam onto the isocenter could be set within an angular range of 240°. The system would be compact requiring a . The range of helium-3 ions makes them suitable for radiosurgery in the brain and breast treatments and are advantageous compared to protons due to the smaller lateral penumbra. This proposed system is unfortunately no longer under development.
6.I.2. Cyclotron and gantry
The combination of a cyclotron with gantry already exists in clinical use. See Section 3.D.1.
6.I.3. LINAC and gantry
By using high gradient LINAC structures (at least 35 MV/ m) with C-band rf, it may be possible to integrate components of the ADAM LIGHT system onto a gantry. This has been proposed as the TUrning LInac for Protontherapy (TULIP) 71 concept, shown in Fig. 25 . The TULIP has an estimated mass of 60 tons. Given the combined attributes of high flux, 5 ms electronic energy changes, and small spot size, TULIP may be ideally suited to proton LIVMAT (See Section 7.A.3) deliveries.
6.J. Gantryless solutions
Current gantries add to the capital cost and space requirements for a particle therapy installation. Fixed beams have been commonly used in particle therapy and are especially prevalent in carbon ion therapy due to the high cost of carbon-ion gantries. There are emerging solutions that aim to improve the utilization and accuracy of horizontal beam treatments. The use of a treatment chair expands the clinical indications that could be treated by horizontal beams however immobilization of patients in chairs is problematic. Ideally, the patient is treated in the same geometry as was used for treatment planning. This challenge was addressed previously at the Fermi National Accelerator Laboratory 72 where a commercial CT scanner was integrated for vertical scanning of the patients treated in a seated or standing position by a horizontal fast neutron beam. Currently, the concept is being commercialized by P-Cure, Ltd, Israel. The space available for the first installation of the Advanced Oncotherapy (produced by ADAM SA) LIGHT system in two cojoined grade II listed row-houses in the center of London precluded a gantry. 73 Instead, the P-cure system is used as part of the spaceefficient installation, as shown in Fig. 26 .
NEW HORIZONS: BEAM DELIVERY SYSTEMS
7.A. Static target conformity
Amongst particle therapy experts, better dose conformality to the target was never the primary stated reason for using particle therapy; instead, limiting the dose to normal critical structures was the primary reason. Nevertheless, x-ray beam proponents argue that conformality is a major factor in achieving excellent clinical results. There are several ways to increase conformality and conformal avoidance.
The transition to IMPT will be complete soon. Without an aperture, scanned dose distribution quality is dependent on the spatial standard deviation of the Gaussian pencil beam lateral intensity distribution at isocenter, or sigma. 29, 30 This can be especially pronounced for fields requiring the use of a physical range shifter. There is and will continue to be, therefore, an effort to regain the lateral dose conformity achieved by collimated beams. The development needs to surpass this conformity, exceeding the dose gradients achievable in the high dose region of the best photon techniques, while retaining the low-medium dose sparing of particle therapy. The following continued developments will occur to support this need:
• Scanned beam trimming collimation devices • Use of multiple spot sizes within the same field • Scanned mini and microbeams One method to achieve better conformality, at least for a single beam direction, is to reduce the large lateral penumbra of scanned proton beams by use of a collimator. This has been done in the past with fixed patient-specific apertures. Recently, a computer controlled multileaf trimming collimator has been developed which can be moved to the edge of each scanned line and for each energy. Because of multiple Coulomb scattering, proton spot size reduction by physical trimming is most effective at shallow-medium depth (see Fig. 27 ). Note that spot trimming, i.e., cutting the peripheral, lateral tail of a proton beam spot is different from collimated beam formation from an over-scattered or over-scanned field such as with uniform scanning or wobbling. 35 Studies have suggested the benefit of spot trimming is limited to less than 160 MeV. 74 These factors reduce the thickness requirement for a spot trimmer, enabling a class of lightweight trimmers.
Patient-specific collimators could also serve this need, but their cost, custom fabrication, and workflow efficiency disadvantages are not attractive in comparison to automated devices. Another disadvantage to the reintroduction of any beam trimming device is undesirable out-of-field dose, primarily from (p,n) inelastic processes. An example of an automated, motor-driven spot trimmer is presented in Fig. 28 . A similar concept of mounting a spot trimming multileaf collimator on a lateral traveling sled was recently realized commercially for the Mevion Hyperscan system.
The potential clinical delivery improvement by spot trimming was reported in a retrospective study of five intracranial cases. 75 A representative result is presented in Fig. 29 where the rightmost subfigure indicates the dose difference between nontrimmed and spot trimmed delivery. The difference is notable in the penumbra high dose gradient portions of the plan, exactly where improvement is needed.
7.A.2. Small scanned proton beams
Smaller sigma proton beamlets, mini-(<1.5 mm) and microbeams (<1 mm) have the potential to improve target conformity without the disadvantages associated with physical trimming devices. The number of beam spots required per layer will scale according to the square of the spot size, however, effectively decreasing the dose delivery rate. Given this factor, mini and microbeams are suggested for the following roles:
• Limited field size (<10 cm) applications where maximum conformity is required.
• As a field edge dose gradient enhancer when used together with larger spot sizes within the same field. A recent report of a scanned proton minibeam delivery development stated that a commercial proton therapy system was specially modified to produce scanned minibeams without collimation. 77 The resulting spot sigma was reported to be 1.4 mm at 221 MeV at the isocenter and below 1 mm at proximal distances. Comparative treatment planning results between regular IMPT and minibeam IMPT indicated target conformity improvement for the representative small and large intracranial targets considered (Fig. 30 ).
Mini and microbeam systems are also associated with proximal dose sparing. The beamlets are widely spaced at the entrance, and spread out due to MCS, giving the uniform dose in the target. One study using spatially fractionated proton minibeams looked at shallow dose-sparing effects of mice ears. The study was extended to investigate mouse ear vasculature effects comparing conventional scanned beam and spatially fractionated minibeams. An example of the difference between scanned minibeam and conventional scanned proton beams is shown in Fig. 31 . 78 The same average dose was used over the irradiated area. Whereas "no ear swelling or other skin reactions were observed at any point after minibeam irradiation, significant ear swelling (up to fourfold), erythema, and desquamation developed inhomogeneously irradiated ears 3-4 weeks after irradiation." The study suggests further potential for clinical benefit from microbeam techniques.
7.A.3. Number of beam angles
Another method to increase target conformity is to use additional beam entry angles per treatment session. This requires rotation of the beam delivery gantry or rotation of the patient with respect to a fixed direction beamline. The ultimate expression of this is LIVMAT. Recent studies have suggested LIVMAT treatments may be more conformal and additionally sparing in whole body dose. Concerns about the delivery robustness of arc plans are also being addressed in optimization. An example of this approach is presented in Fig. 32 for a lung target. 79 Similar results have been found for other target geometries and sites. 80 Challenges in LIVMAT delivery include gantry capability and delivery speed. The speed is dependent on spot size, beam flux, and the time required to change energy.
7.A.4. Contour scanning patterns
Current scanning planning and delivery systems follow rectilinear grid spot placements. Whereas machine specific QA targets often have a square profile, patient targets do not. The mismatch between a patient target contour and the treatment planning/delivery square spot placement grid can result in reduced conformity. One solution to this is to plan and apply the beam spots along the target contour -this is referred to as contour scanning. 81 An example of the potential improved conformity advantage of contour over rectangular grid scanning is shown in Fig. 33 . Similar to spot trimming and mini/microbeams, contour scanning reduces dose in neighboring structures. In principle, the contour scanning technique could also be applied to spot trimming and mini/ microbeams as well, further enhancing them. Another possible improvement could be to use other geometric scanning patterns such as a hexagonal grid, or spiral patterns. A study considering hexagonal scan patterns indicated that a more robust dose distribution might be provided with fewer spots due to the overlap. 82 
7.A.5. Ions other than protons
Due to their heavier masses and reduced MCS in comparison to protons, other ions such as carbon and helium may offer conformity advantages. The potential biological advantages and challenges of light ion treatments are discussed in some of the companion articles in this issue. Regarding physical dose distribution properties, the amount of MCS is the fundamental parameter. Although protons provide longitudinal target dose sparing in comparison to photons, the observation from Fig. 34 (Ref. 84) suggests reduced MCS is needed to further improve the therapeutic index for targets deeper than 17 cm, in water equivalence. According to MCS theory, heavier masses scatter less. Therefore, heavier particles are attractive for therapy in this regard. The achievable lateral conformity is also related to beamlet size, usually characterized according to the Gaussian distribution r in the air, or at depth in media, usually water. Figure 34 illustrates the effect of MCS on protons and particle therapy beams in water, showing the potential lateral physical dose delivery superiority of the more massive particles over protons.
Here we specifically make a case for developing helium ion systems as the next step to wider light ion therapy adoption. Carbon ion therapy is practiced at a few large institutions worldwide and accounts for about 10% of all particle therapy treatments. Although additional carbon ion facilities are expected to launch, the growth will remain very low due to the associated size and cost. Instead, we expect helium ion delivery opportunities to expand at a greater rate. Fundamentally, the reasons for this are: Farr et al.: Advanced particle therapy systems e979
• Lateral scattering in tissue is about half that of protons.
• Lateral penumbra is sharper next to organs at risk.
• Mass of 4 amu compared to 12 C does not require as much total accelerating energy (smaller accelerators).
• Intermediate biological effectiveness, so possibly applicable to more pediatric indications than carbon ions.
• Minimal fragmentation tail (in comparison to heavier particle therapy)
• Possible hybrid "biological painting" together with protons.
The enthusiasm for further helium development also has a basis in the excellent patient outcomes, including low toxicity, that was observed in a feasibility project at the Lawrence Berkley Laboratory, where over 2000 patients were treated with 4 He-ions in the 1970-1980's. 42 The trials were performed with a classic scattering foil broad beam (not scanned beam). Therefore proximal conformity is expected to improve using current therapy delivery methods.
In a comparative study between protons, helium, and carbon ions, a representative base of skull case was evaluated for biologically weighted brainstem dose (Fig. 35) . The authors reported the ratio of biologically equivalent doses were 1.00:0.44:0.32, for proton:helium: carbon. The study suggests that helium and carbon ions have the potential to provide greater patient protection in such cases. This further supports the idea of exploring helium delivery systems as a cost-effective alternative to carbon ions.
7.A.6. Delivery robustness and adaptation
Since the early 1990s, ion beam delivery systems have utilized redundant multielement beam monitoring systems with automatic feedback to control the beam. This has made the delivery quite robust concerning beam quality. On the other hand, the interaction of patient characteristics with some beam characteristics, such as heterogeneities within the patient, lack of gantry angles, and passage of the beam through table top edges and other immobilization devices has resulted in the overall treatments not being robust. Future improvements in rotating gantries, patient positioners, and immobilization devices should improve the overall treatment robustness.
One of the major problems facing treatments in the abdomen with scanning beams is day-to-day variations in anatomy. It is now feasible to install CT scanners in the ion beam treatment rooms to acquire 3D patient data immediately before each treatment. One issue with such an arrangement is the interaction between the high power CT scanner currents and the sensitive ion beam monitors. Currently, Siemens recommends powering off the CT scanner before each ion beam delivery. This requires a cold restart for each patient scan reducing the patient throughput of the room. Another aspect of daily adaptive therapy is to have a TPS in the treatment control room. Currently, Monte Carlo dose calculations with GPUs can be done in less than 20 s, but reoptimization takes somewhat longer. Within the next 3 years, daily adaptive therapy will probably become a reality. The next challenge will be developing a process for quickly approving and implementing the new plan.
7.B. Robust and advanced delivery development for moving targets
As described in greater detail in this issue ("Motion management in particle therapy"), there are many techniques to mitigate the effects of target motion. Currently, most medical physicists prefer stopping the motion, typically with breath hold or compression techniques. Beam gating is another method currently used, but this has a larger associated residual motion and more prolonged treatment time. Also, there are no genuinely 4D treatment planning systems to fully support these motion treatments. Other more technically challenging techniques are available or proposed, a couple of which are given in the following subsections.
7.B.1. Rescanning
Rescanning (sometimes called repainting) has been available for many years in various forms but has seldom been used because it slows the treatment, increases the lateral penumbra, and decreases distal conformality. Volumetric or 3D rescanning can be performed automatically or manually by just splitting the daily dose and delivering the whole portal multiple times. Unfortunately, due to the proportional number of energy changes required and long energy change time, 3D rescanning is not practically realized in the clinic. Millisecond energy changes, sufficient flux, and lateral scanning speed are required to enable volumetric repainting.
Lateral or 2D rescanning, sometimes called layer rescanning, can avoid these multiple energy changes and thus does not extend the treatment time as much as 3D rescanning. Also, because the lateral scanning is relatively fast, it does not blur the dose distribution in depth as much as 3D scanning. Energy layer rescanning was implemented in the 2006 DICOM standard for ion beams. 84 2D, layer rescanning is available from multiple delivery systems.
7.B.2. Target tracking with active range control
Active target following with particle therapy could have a high impact on some patient outcomes. To track the target in 3D, lateral and path length changes must be accommodated. Lateral tracking can be performed with scanning magnets. Although a mechanical system for relatively fast range changes in combination with scanning was investigated 85, 86 as far back as 2004, no system has yet made it into clinical use. Fast, electronic energy control is attractive for active range control applications. Here, the LINAC pulse-by-pulse energy change potential described in Section 6.D could be fully exploited.
SUMMARY AND CONCLUSIONS
Much progress has been made with particle beam treatment systems. Current systems are smaller, lighter, and more readily suited to regular clinical practice than ever before. However, further developments are needed to realize the full promise of particle therapy. The needed developments are in two areas: (a) beam quality and treatment delivery time, and (b) size and cost. The size and cost needs will probably be met by the further development of existing accelerator technology (cyclotrons, synchrotrons, synchro-cyclotrons, and LINACs), as opposed to new technology from an unknown disruptive entity. The necessary treatment quality improvements will come from a reduction in uncertainties (see other articles 2018 (in this issue)) together with advanced particle treatment systems. The advanced treatment systems will include further proton therapy target conformity improvement through a combination of physical means and spot size reduction, followed by a gradual transition to other ions, especially helium. As delivery system speed increases, mainly through a reduction in energy changing time, the drive to greater target conformity will also occur for moving targets with volumetric rescanning and, ultimately, target tracking with active range control. FIG. 35 . Base of a skull tumor abutting brainstem: comparison between proton, helium, and carbon ion treatment plans, restyled after Gruen, et al. 87 Medical Physics, 45 (11), November 2018 e981
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